Vaccine compositions comprising a saponin adjuvant
AssigneeGlacoSmithKline Biologicals, S.A.
InventorPierre Vandepapeliere
Life of this patent
Estimating the term…
Abstract
The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome.
Claims13
A method of vaccination of a human individual comprising intramuscular delivery of a human dose of an immunogenic composition comprising an antigen in combination with an adjuvant, which adjuvant comprises the QS21 saponin fraction of Quil A from the bark of Quillaja saponaria Molina presented in the form of a liposome and a lipopolysaccharide, wherein said saponin fraction and said lipopolysaccharide are each present in said human dose at a level of about 25 μg, wherein the antigen is selected from the group consisting of a Moraxella catarrhalis protein antigen and a non-typeable Haemophilus influenzae protein antigen, wherein said adjuvant further comprises a sterol, wherein the ratio of saponin:sterol is from 1:1 to 1:100 w/w.
A method of vaccination of a human individual comprising intramuscular delivery of a human dose of an immunogenic composition comprising an antigen selected from the group consisting of a Moraxella catarrhalis protein antigen and a non-typeable Haemophilus influenzae protein antigen, in combination with an adjuvant, which adjuvant comprises the QS21 saponin fraction of Quil A from the bark of Quillaja saponaria Molina presented in the form of a liposome and a lipopolysaccharide, wherein said saponin fraction and said lipopolysaccharide are each present in said human dose at a level of below 30 μg.
Dependencies are inferred from the claim text.